Navigation Links
Favrille Announces Results From Study Showing Enhanced Activity,From Insect Cell-Derived Immunotherapy for Lymphoma

Data Reported at American Association for Cancer Research Annual Meeting

SAN DIEGO, April 18, 2007 /PRNewswire-FirstCall/ -- Favrille, Inc. , a biopharmaceutical company developing patient-specific, active immunotherapies for the treatment of cancer, announced results from a new study showing enhanced activity from insect-cell derived idiotype (Id) proteins, a key component in the Company's Id/KLH immunotherapy product candidate FavId(R) for B-cell non-Hodgkin's lymphoma (NHL), compared to Id proteins produced using mammalian cells. The data were reported today at the American Association for Cancer Research (AACR) Annual Meeting in Los Angeles.

"Our data show that production of recombinant Id proteins via an insect cell system results in a structurally different antigen with improved immunogenicity compared to mammalian cell-derived Id proteins," said co-author John Timmerman, M.D., and Assistant Professor of Medicine, Division of Hematology and Oncology at the University of California, Los Angeles, where much of the study was performed. "This in turn may lead to improved activity of the final Id-KLH immunotherapy for lymphoma."

A copy of the poster presented by Dr. Timmerman, entitled "Enhanced Immunostimulation by a Therapeutic Lymphoma Idiotype Vaccine Produced in Insect Cells Involves Mannose Receptor Targeting to Antigen Presenting Cells," is now available on the Investor Relations section of Favrille's web site at

"This study demonstrates that Id protein produced by insect cell lines possesses an enhanced ability to interact with dendritic cells compared to the same protein produced in mammalian cells, which in turn stimulates an enhanced immune response," said Daniel Gold, Ph.D., Favrille's Chief Scientific Officer. "These data help support our belief that the use of insect cells provides not only the most eff icient method for producing Id/KLH immunotherapies, but also the added advantage of making them potentially more active as well."

About FavId

FavId is a patient-specific, Id/KLH active immunotherapy for the treatment of B-cell NHL. Favrille completed enrollment in its pivotal Phase 3 clinical trial of FavId following Rituxan(R) induction therapy in patients with follicular B-cell NHL in January 2006. Analysis of the primary endpoint, time to disease progression, is event driven and currently projected to occur during the fourth quarter of 2007. The Company has a Special Protocol Assessment from the U.S. Food and Drug Administration (FDA) for its Phase 3 trial, and has also received Fast Track designation for FavId from the FDA.

About Favrille, Inc.

Favrille, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system. The Company's lead product candidate, FavId, is based upon unique genetic information extracted from a patient's tumor. FavId is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-cell NHL indications. The Company is developing additional applications based on its immunotherapy expertise and proprietary cost- effective manufacturing technology, including a second product candidate, FAV- 201, for the treatment of cutaneous T-cell lymphoma.

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Favrille's product candidates, proprietary technologies and research programs. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Favrille's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to progress and timing of clinical trials for FavId, including difficulties or delays in development, testing, manufacturing and marketing FavId or Favrille's other product candidates; Favrille's ability to obtain marketing approval for FavId or Favrille's other product candidates and the timing of any such approvals; Favrille's ability to manufacture sufficient quantities of FavId for use in clinical trials and, if FavId receives marketing approval, for commercialization; risks associated with achieving projected operating metrics and financial performance or the anticipated number of patients using FavId; potential delays in patient enrollment; Favrille's ability to obtain additional financing to support its operations; and additional risks discussed in Favrille's filings with the Securities and Exchange Commission. In addition, conclusions regarding the safety and efficacy of Favrille's product candidates cannot be made until the results of future clinical trials of longer duration in more patients are known. All forward-looking statements are qualified in their entirety by this cautionary statement. Favrille is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward- looking statements contained in this release as a result of new information, future events or otherwise.

CONTACT: Tamara A. Seymour, CFO and Vice President, Finance &Administration, +1-858-526-8035, , or Pete De Spain,Associate Director, Investor Relations & Corporate Communications,+1-858-526-2426, , both of Favrille, Inc.

Web site: http://www.favril

Ticker Symbol: (NASDAQ-NMS:FVRL)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. Favrille Announces Data From Phase 2 Clinical Trial of FavId for Indolent B-Cell Non-Hodgkins Lymphoma in Europe
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:11/25/2015)... DUBLIN , Nov. 25, 2015 /PRNewswire/ ... announced the addition of the "Global ... to their offering. --> ... "Global Brain Monitoring Devices Market 2015-2019" ... Research and Markets ( ) ...
(Date:11/25/2015)... 2015  The American Academy of Pediatrics (AAP), ... the March of Dimes cheered today,s signature into ... Act of 2015 (S.799), which takes much-needed ... exposed to drugs, such as opioids, and to ... three organizations have worked together leading advocacy efforts ...
(Date:11/25/2015)... On Tuesday, November 24, 2015, the ... Wright Medical Technology, Inc. for product liability and ... implant device, awarded $11 million in favor of ... and three days of deliberations, the jury found ... designed and unreasonably dangerous, and that Wright Medical ...
Breaking Medicine Technology:
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... contact center software Q-Suite, announces the incorporation of Asterisk 11 LTS (Long Term ... fully supported Asterisk 11 LTS brings Q-Suite 5.10 up-to-date with a version of ...
(Date:11/26/2015)... ... November 26, 2015 , ... Inevitably when people think Thanksgiving, they also ... buy during the Black Friday and Cyber Monday massage chair sales to ... Internet high and low to find the best massage chair deals, they can see ...
(Date:11/26/2015)... , ... November 26, 2015 , ... ... Express Travel Representative. As a franchise owner, Somu now offers travelers, value and ... destination wedding packages, private cruise sales, as well as, cabin upgrades and special ...
(Date:11/26/2015)... ... November 26, 2015 , ... Jobs in hospital medical laboratories and ... offered by healthcare staffing agency Aureus Medical Group . These fields, ... 2015 among those searching for healthcare jobs through the company’s website, ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... opinion process, participated in the 61st annual Employee Benefits Conference. The Employee Benefits ... place Sunday, November 8th through Wednesday, November 11th, 2015. The conference was held ...
Breaking Medicine News(10 mins):